Alec Freyn, PhD

Moderna Inc
Cambridge, Massachusetts, United States

Disclosure information not submitted.

Presentation(s):

• 642 - mRNA-1608, an mRNA-Based Therapeutic Genital Herpes Vaccine Candidate: Interim Safety, Immunogenicity and Clinical Endpoint Results from a Phase 1/2, Randomized, Observer-Blind, Controlled, Dose-Ranging Trial

  Wednesday, October 22, 2025
  1:57 PM - 2:09 PM US ET